Dr. Kumar on Next Steps for Venetoclax in Multiple Myeloma

Shaji K. Kumar, MD
Published: Thursday, Feb 09, 2017



Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Venetoclax, a BCL-2 inhibitor, has been generally well tolerated in trials, says Kumar. Toxicities have been manageable, suggesting it would be an option to explore in combination regimens.

According to Kumar, next steps include identifying a subset of patients who are sensitive to the drug through a multi-pronged approach of the combination of venetoclax plus dexamethasone in relapsed multiple myeloma.

Currently, a phase III trial is accruing to evaluate the combination of venetoclax and bortezomib (Velcade) as well.
 
SELECTED
LANGUAGE


Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Venetoclax, a BCL-2 inhibitor, has been generally well tolerated in trials, says Kumar. Toxicities have been manageable, suggesting it would be an option to explore in combination regimens.

According to Kumar, next steps include identifying a subset of patients who are sensitive to the drug through a multi-pronged approach of the combination of venetoclax plus dexamethasone in relapsed multiple myeloma.

Currently, a phase III trial is accruing to evaluate the combination of venetoclax and bortezomib (Velcade) as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x